Physician profile
Kailash Kedia
NPI 1548240286
$33,628.98
in general payments reported to CMS, 2019-2025
62 companies · $8,598 in 2025
The $8,598 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,006 · 2020: $3,030 · 2021: $2,141 · 2022: $2,763 · 2023: $3,973 · 2024: $4,119 · 2025: $8,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $2,682 · Consulting Fee: $1,500 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,213.71 |
| Travel and Lodging | $2,681.87 |
| Consulting Fee | $1,500.00 |
| Education | $293.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Gpo, LLC | $6,703.36 | 2019 | |
| Dendreon Pharmaceuticals LLC | $4,381.05 | 2019-2025 | Provenge |
| Coloplast Corp | $3,066.24 | 2019-2025 | Titan, Saffron, Altis |
| Procept Biorobotics Corporation | $2,790.42 | 2021-2025 | Aquabeam System, Aquabeam Robotic System |
| Pfizer INC. | $1,758.23 | 2019-2025 | |
| Astellas Pharma US INC | $1,518.18 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $1,244.31 | 2023-2025 | Orgovyx, Gemtesa |
| Olympus America INC. | $1,066.61 | 2022-2025 | Itind System, Bovie, Hd Camera Head |
| Uc-Care (USA), INC | $911.07 | 2023 | Navigo Workstation |
| Astrazeneca Pharmaceuticals LP | $766.79 | 2019-2025 | Airsupra, Lynparza |
| Myovant Sciences INC. | $754.71 | 2021-2022 | |
| Axonics, INC. | $656.44 | 2020-2024 | Axonics, Bulkamid |
| Janssen Biotech, INC. | $611.74 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Myriad Genetic Laboratories, INC. | $514.95 | 2022-2025 | Prolaris, Myrisk, Precisetumor |
| Blue Earth Diagnostics | $466.74 | 2020-2025 | Posluma |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kailash Kedia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.